Salix Pharmaceuticals Newswire (Page 2)

Salix Pharmaceuticals Newswire (Page 2)

Comprehensive Real-Time News Feed for Salix Pharmaceuticals. (Page 2)

Results 21 - 40 of 82 in Salix Pharmaceuticals

  1. Check Cap (CHEK) and Salix Pharmaceuticals (SLXP) Head-To-Head SurveyRead the original story w/Photo

    Dec 24, 2017 | The Breeze

    Check Cap and Salix Pharmaceuticals are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk. Salix Pharmaceuticals is trading at a lower price-to-earnings ratio than Check Cap, indicating that it is currently the more affordable of the two stocks.

    Comment?

  2. Parkinson's Disease Therapeutics Market Grows with Increasing Prevalence of ParkinsonismRead the original story w/Photo

    Dec 21, 2017 | SBWire

    ... of the key players in global Parkinson's disease therapeutics market include GlaxoSmithKline Plc., Salix Pharmaceuticals, mpax Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Orion Corporation, Mylan N.V. while generic players ...

    Comment?

  3. Reviewing Salix PharmaceuticalsRead the original story w/Photo

    Dec 19, 2017 | AmericanBankingNews.com

    Salix Pharmaceuticals and Check Cap are both specialty & advanced pharmaceuticals companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Check Cap has a consensus price target of $5.50, suggesting a potential upside of 485.11%.

    Comment?

  4. What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?Read the original story w/Photo

    Dec 8, 2017 | Fox News

    ... a number of noncore assets. This suggest that not only are its two core businesses, Bausch & Lomb and Salix Pharmaceuticals, holding their ground, but that its debt covenants are, for the meantime, on reasonably solid footing. Valeant sports an ...

    Comment?

  5. Financial Contrast: Salix Pharmaceuticals (SLXP) vs. The CompetitionRead the original story w/Photo

    Dec 4, 2017 | The Breeze

    Salix Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it weigh in compared to its peers? We will compare Salix Pharmaceuticals to related companies based on the strength of its dividends, earnings, institutional ownership, profitability, risk, analyst recommendations and valuation. Salix Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

    Comment?

  6. Contrasting Aimmune TherapeuticsRead the original story w/Photo

    Dec 4, 2017 | Daily Political

    Aimmune Therapeutics and Salix Pharmaceuticals are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability. 73.3% of Aimmune Therapeutics shares are owned by institutional investors.

    Comment?

  7. Comparing Eagle PharmaceuticalsRead the original story w/Photo

    Dec 4, 2017 | The Breeze

    Eagle Pharmaceuticals and Salix Pharmaceuticals are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Eagle Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

    Comment?

  8. Salix Pharmaceuticals (SLXP) versus Its Competitors Head-To-Head ContrastRead the original story w/Photo

    Dec 3, 2017 | AmericanBankingNews.com

    Salix Pharmaceuticals is one of 19 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it compare to its peers? We will compare Salix Pharmaceuticals to similar companies based on the strength of its valuation, institutional ownership, profitability, dividends, earnings, risk and analyst recommendations. 65.0% of shares of all "Specialty & Advanced Pharmaceuticals" companies are held by institutional investors.

    Comment?

  9. Critical Analysis: Eagle PharmaceuticalsRead the original story w/Photo

    Dec 1, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals and Salix Pharmaceuticals are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Eagle Pharmaceuticals has higher revenue and earnings than Salix Pharmaceuticals.

    Comment?

  10. Salix Pharmaceuticals (SLXP) versus Its Rivals Critical AnalysisRead the original story w/Photo

    Nov 28, 2017 | Daily Political

    Salix Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Salix Pharmaceuticals to similar companies based on the strength of its analyst recommendations, earnings, profitability, institutional ownership, risk, valuation and dividends. 65.0% of shares of all "Specialty & Advanced Pharmaceuticals" companies are owned by institutional investors.

    Comment?

  11. ZappRx Bolsters Company Growth with Strategic Executive Hires, and...Read the original story

    Nov 28, 2017 | Customer Interaction Solutions

    ... UCB Biopharma's Immunology and Bone business units. Prior to UCB, Cornicelli spent 13 yearsat Salix Pharmaceuticals, which was ultimately acquired for $15 billion under his guidance. Mr. Kramer will lead ZappRx's provider account management team as ...

    Comment?

  12. Salix Pharmaceuticals (SLXP) versus Its Competitors Head to Head AnalysisRead the original story w/Photo

    Nov 25, 2017 | IntersportsWire

    Salix Pharmaceuticals is one of 19 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Salix Pharmaceuticals to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Salix Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

    Comment?

  13. Financial Comparison: Salix Pharmaceuticals (SLXP) & Its CompetitorsRead the original story w/Photo

    Nov 22, 2017 | AmericanBankingNews.com

    Salix Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it compare to its competitors? We will compare Salix Pharmaceuticals to related businesses based on the strength of its analyst recommendations, valuation, dividends, earnings, risk, profitability and institutional ownership. 64.5% of shares of all "Specialty & Advanced Pharmaceuticals" companies are owned by institutional investors.

    Comment?

  14. Analyzing Salix Pharmaceuticals (SLXP) & The CompetitionRead the original story w/Photo

    Nov 21, 2017 | Daily Political

    Salix Pharmaceuticals is one of 19 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it compare to its rivals? We will compare Salix Pharmaceuticals to similar companies based on the strength of its risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings. Salix Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

    Comment?

  15. Analyzing Salix Pharmaceuticals (SLXP) and Its CompetitorsRead the original story w/Photo

    Nov 19, 2017 | AmericanBankingNews.com

    Salix Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its peers? We will compare Salix Pharmaceuticals to similar businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations. This is a breakdown of current ratings and price targets for Salix Pharmaceuticals and its peers, as reported by MarketBeat.

    Comment?

  16. Critical Review: Salix Pharmaceuticals (SLXP) vs. Its CompetitorsRead the original story w/Photo

    Nov 19, 2017 | AmericanBankingNews.com

    Salix Pharmaceuticals is one of 19 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it compare to its competitors? We will compare Salix Pharmaceuticals to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings. Salix Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

    Comment?

  17. Financial Review: Salix PharmaceuticalsRead the original story w/Photo

    Nov 15, 2017 | AmericanBankingNews.com

    Salix Pharmaceuticals and TherapeuticsMD are both specialty & advanced pharmaceuticals companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. 72.5% of TherapeuticsMD shares are owned by institutional investors.

    Comment?

  18. Valeant: Salix Growth Might Start To Replace Asset Sales In 2018Read the original story w/Photo

    Nov 13, 2017 | Seeking Alpha

    Valeant Pharmaceuticals International Inc. spent a boat load of money in 2015 acquiring Salix Pharmaceuticals right before drug pricing scandals started hitting the company later that year. Since then Valeant has been in survival mode with all of its segments suffering until recently, when growth and stability have again started showing up in its business segments.

    Comment?

  19. Reviewing Salix Pharmaceuticals (SLXP) and Its RivalsRead the original story w/Photo

    Nov 10, 2017 | IntersportsWire

    Salix Pharmaceuticals is one of 20 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Salix Pharmaceuticals to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation. This is a breakdown of current ratings and target prices for Salix Pharmaceuticals and its rivals, as provided by MarketBeat.com.

    Comment?

  20. Controlled-Release Drug Delivery Technology Market show exponential growth by 2027Read the original story w/Photo

    Nov 6, 2017 | PR-inside.com

    ... formulations such as NUCYNTA ER, Gralise (Depomed Inc.), Janumet XR (Merck), Glumetza (Salix Pharmaceuticals) etc. Wurster coating technology is being used in the drug coating for controlled release of drug since 1976. Corplex transdermal technology ...

    Comment?